{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Based on negative results from trial NCT00634725 regarding the question of gemcitabine versus gemcitabine plus erlotinib in locally unresectable pancreatic cancer patients, this study was amended to stop the erlotinib randomization and to change the erlotinib question to a randomized phase II design using the patients already randomized."},"pointOfContact":{"email":"seiferheldw@nrgoncology.org","organization":"NRG Oncology","phone":"2155743208","title":"Wendy Seiferheld"}}